Author
Listed:
- Zeynep Eroglu
(University of California Los Angeles
Moffitt Cancer Center and University of South Florida)
- Jesse M. Zaretsky
(University of California Los Angeles)
- Siwen Hu-Lieskovan
(University of California Los Angeles)
- Dae Won Kim
(Moffitt Cancer Center and University of South Florida
The University of Texas-MD Anderson Cancer Center)
- Alain Algazi
(University of California San Francisco)
- Douglas B. Johnson
(Vanderbilt Ingram Cancer Center)
- Elizabeth Liniker
(Melanoma Institute Australia)
- Ben Kong
(Westmead Hospital)
- Rodrigo Munhoz
(Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College)
- Suthee Rapisuwon
(Georgetown Lombardi Cancer Center)
- Pier Federico Gherardini
(Parker Institute for Cancer Immunotherapy)
- Bartosz Chmielowski
(University of California Los Angeles)
- Xiaoyan Wang
(University of California Los Angeles)
- I. Peter Shintaku
(University of California Los Angeles)
- Cody Wei
(University of California Los Angeles)
- Jeffrey A. Sosman
(Vanderbilt Ingram Cancer Center
Northwestern University Medical Center)
- Richard W. Joseph
(Mayo Clinic)
- Michael A. Postow
(Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College)
- Matteo S. Carlino
(Melanoma Institute Australia
Westmead Hospital
The University of Sydney)
- Wen-Jen Hwu
(The University of Texas-MD Anderson Cancer Center)
- Richard A. Scolyer
(Melanoma Institute Australia
The University of Sydney
Royal Prince Alfred Hospital)
- Jane Messina
(Moffitt Cancer Center and University of South Florida)
- Alistair J. Cochran
(University of California Los Angeles)
- Georgina V. Long
(Melanoma Institute Australia
The University of Sydney
Royal North Shore Hospital)
- Antoni Ribas
(University of California Los Angeles)
Abstract
Immune checkpoint blockade with anti-PD-1 or anti-PD-L1 agents produces a high response rate in patients with desmoplastic melanoma.
Suggested Citation
Zeynep Eroglu & Jesse M. Zaretsky & Siwen Hu-Lieskovan & Dae Won Kim & Alain Algazi & Douglas B. Johnson & Elizabeth Liniker & Ben Kong & Rodrigo Munhoz & Suthee Rapisuwon & Pier Federico Gherardini &, 2018.
"High response rate to PD-1 blockade in desmoplastic melanomas,"
Nature, Nature, vol. 553(7688), pages 347-350, January.
Handle:
RePEc:nat:nature:v:553:y:2018:i:7688:d:10.1038_nature25187
DOI: 10.1038/nature25187
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:553:y:2018:i:7688:d:10.1038_nature25187. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.